101 related articles for article (PubMed ID: 22233408)
1. Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P
J Viral Hepat; 2012 Jan; 19 Suppl 1():7-13. PubMed ID: 22233408
[TBL] [Abstract][Full Text] [Related]
2. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.
Ferenci P
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):463-9. PubMed ID: 23199505
[TBL] [Abstract][Full Text] [Related]
3. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Scherzer TM; Stättermayer AF; Strasser M; Laferl H; Maieron A; Stauber R; Datz C; Dulic-Lakovic E; Steindl-Munda P; Hofer H; Ferenci P
Hepatology; 2011 Nov; 54(5):1518-26. PubMed ID: 22006276
[TBL] [Abstract][Full Text] [Related]
4. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P
J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807
[TBL] [Abstract][Full Text] [Related]
5. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
6. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
[TBL] [Abstract][Full Text] [Related]
7. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
9. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Sarrazin C; Shiffman ML; Hadziyannis SJ; Lin A; Colucci G; Ishida H; Zeuzem S
J Hepatol; 2010 Jun; 52(6):832-8. PubMed ID: 20385421
[TBL] [Abstract][Full Text] [Related]
10. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
11. Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area.
Chung HJ; Lee JW; Kim YS; Lee JI
Intervirology; 2013; 56(3):178-83. PubMed ID: 23306941
[TBL] [Abstract][Full Text] [Related]
12. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
[TBL] [Abstract][Full Text] [Related]
13. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
Nakagawa A; Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Arai T; Hashimoto S; Matsushita Y; Fukuda T; Nakatsuka K; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1329-34. PubMed ID: 25357216
[TBL] [Abstract][Full Text] [Related]
14. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
[TBL] [Abstract][Full Text] [Related]
15. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
18. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
[TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.
Berg T; Carosi G
Antivir Ther; 2008; 13 Suppl 1():17-22. PubMed ID: 18432159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
